Novartis AG's gene therapy Zolgensma generated $160m in the third quarter, its first full quarter on the market, a strong launch for any new drug in today's challenging launch environment. Zolgensma (onasemnogene abeparvovec) is not the first gene therapy to reach the market in the US or Europe, but it looks like it will be the first to attain commercial traction.
Novartis's Zolgensma Finds Commercial Legs In A First For Gene Therapy
Zolgensma generated $160m in the third quarter, a strong launch for the gene therapy's first full quarter on the market.
More from Earnings
More from Business
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.